
Jun 8, 2026 · 7 min
S&P inclusion lifts Marvell and Flex as tech stocks rebound
Marvell Rallies on S&P Add; Micron Rebounds; Lilly Gains on Obesity Drugs
The episode examines how index-fund flows, a tech-sector recovery, and drug-market competition are reshaping individual stock valuations.
- 1Marvell Technology and Flex gain after joining the S&P 500, highlighting the market impact of passive investment funds.
- 2Micron Technology rebounds after a sharp technology sell-off, while broader sector momentum remains central to its recovery.
- 3Eli Lilly and Nurix Therapeutics reflect intensifying competition across obesity and cancer treatments.
Don't miss
Marvell Technology and Flex rally after entering the S&P 500, illustrating how passive-fund demand can affect valuations.
The brief
Marvell Technology and Flex rally after their addition to the S&P 500, putting passive investment flows at the center of the market’s reaction.
Micron Technology’s rebound follows a sharp technology sell-off, showing how quickly sentiment can shift across a crowded sector.
The pharmaceutical discussion turns to Eli Lilly and Nurix Therapeutics, where obesity and cancer treatments create distinct competitive pressures.
Taken together, the episode contrasts index-driven demand with company-specific drug developments, asking what is really moving these stocks.
What was said on this episode
6 statements · 5 positive · 1 negative
Markets typically front-run S&P 500 additions because index-tracking funds must buy them.
“markets tend to front run this on the expectation that a lot of funds will have to buy it”
Listen at 1:30
Risk appetite has recovered, and signs of an AI sell-off are stabilizing.
“the risk appetite has turned around over the weekend and signs of an AI sell off are stabilizing today”
Listen at 2:13
Micron is one of three major memory players and the only US-based one.
“Micron in general. It's one of the three major memory players big investment theme for the AI trade and the only one in the US”
Listen at 2:37
Roche agreed to pay up to $2.3 billion for rights to Neurx’s experimental blood-cancer drug.
“Roche has agreed to pay up to $2.3 billion for the rights to Newx's experimental blood cancer drug.”
Listen at 3:12
Neurx’s experimental medicine targets a protein that drives several cancers.
“it's a new class of medicine aimed at eliminating a protein that drives several cancers”
Listen at 3:27
Zealand Pharma’s competing obesity-drug study data disappointed investors.
“that company has a potentially competing obesity drug and data from that study disappointed the stock movers.”
Listen at 4:18
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.